We are dedicated to ensuring diversity of our workforce and are committed to fostering an inclusive, open and supportive work environment across our locations in Europe and the U.S. With the goal to conduct multiple clinical trials in first product, filgotinib for the treatment of RA, across Europe, our organization continues to develop and build expertise, and we are committed to maintaining our corporate DNA.